Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
This is a multicenter, phase 2, randomized trial to evaluate the efficacy and safety of obinutuzumab with CHOP versus obinutuzumab with bendamustine in treatment-naïve follicular lymphoma (Grade 3A) patients.
Follicular Lymphoma Grade 3A
DRUG: Obinutuzumab|DRUG: CHOP|DRUG: Bendamustine
Progression-Free Survival (PFS), From study entry to the first documented disease progression or death from any cause., Assessed up to 5 years.
Complete Response (CR), Defined as the proportion of patients who achieve complete remission at the end of induction therapy., Up to 6 cycles (up to 24 weeks).|Objective Response Rate (ORR), The proportion of patients who achieve complete remission (CR) or partial remission (PR) at the end of induction therapy., Up to 6 cycles (up to 24 weeks).|Event-Free Survival (EFS), From study entry to the first occurrence of any event, including disease progression, discontinuation of treatment, or death for any reason., Assessed up to 5 years.|Overall Survival (OS), From study entry to death from any cause., Assessed up to 5 years.|Progression of Disease within 24 months (POD24), The occurrence of disease progression or relapse within 24 months from the date of enrollment., 24 months.
This is a multicenter, phase 2, randomized trial to evaluate the efficacy and safety of obinutuzumab with CHOP versus obinutuzumab with bendamustine in treatment-naïve follicular lymphoma (Grade 3A) patients.